In part 4 of this Exclusive Interview, Dr. Thomas Seck shares his thought about Empagliflozin as it relates to diabetes professionals in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

In part 5 of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about costs and benefits of Empagliflozin for patients as well as insurance companies.

In part 6 of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the impact of heart disease on the patient with diabetes.

In part 7 of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about what's coming up next for Boehringer Ingelheim and knowing the right patient to treat with the newest drugs.

In part 8 of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about plans to study the effects of Empagliflozin in patients with prediabetes.

In part 9, the conclusion of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the importance of adding diet and exercise to a treatment regimen.

Recently the AHA and ACC tightened up their guidelines for better control. These controls are especially important for diabetes patients. This week, one of our favorite presenters, Dr. Claude Lardinois, M.D., FACP, FACE, MACN, who was recently elected as a Fellow of the American College of Endocrinology, starts a series of Homerun …

Woman, 55 years of age, referred to me for obesity management. She visited without recent labs, so we got started with the agreement she would get her labs drawn soon after her visit. At our first visit, her blood pressure was 150/98, HR 64, and weight 204, BMI-35, therefore her BMI category was class II obesity. PMH-+Migraine Headaches. FH-+Mother died of lung cancer. Her mother was a smoker. Patient is not.

In this week's Homerun Slides, Dr. Claude Lardinois returns with an update on hypertension starting with causes, risk factors, and worldwide mortality rates.

OSA and incident T2DM: Several studies have examined whether having OSA increases the individual’s risk of developing T2DM, in particular whether obesity is a major risk factor for both conditions and whether OSA has been associated with IR and prediabetes as described earlier. Several cross-sectional studies found a higher prevalence of T2DM in patients with OSA despite adjusting for confounders, particularly age and obesity; these studies are reviewed in. Whether OSA is a predictor of T2DM has been examined in a small number of longitudinal studies that used a variety of methods to diagnose OSA (from symptoms to polysomnography), and to diagnose T2DM (from self-reported to OGTT).